Drug Trial Radar · NCT07176390
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
185
Actual
Start
Oct 8, 2025
Primary completion
Sep 7, 2026
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Conditions
- Arthritis, Rheumatoid
Interventions
TulisokibartDrug
Subcutaneous (SC) administration
PlaceboDrug
SC Injection
MethotrexateDrug
Background Therapy - SC injection or oral administration. Per protocol, parenteral administration is allowed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12Time frame: Week 12
Locations
61 sites in 11 countries. Site status is shown where the registry gives one.
Arizona Arthritis & Rheumatology Associates, P.C. ( Site 1018)
Glendale, Arizona
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa ( Site 1033)
Mesa, Arizona
Arthritis & Osteoporosis Medical Center - La Palma ( Site 1024)
La Palma, California
Tekton Research, LLC. ( Site 1008)
Fort Collins, Colorado
Sweet Hope Research Specialty, Inc ( Site 1015)
Hialeah, Florida
HMD Research LLC ( Site 1016)
Orlando, Florida
Greater Chicago Specialty Physicians - Orland Park ( Site 1043)
Orland Park, Illinois
AA Medical Research Center ( Site 1027)
Grand Blanc, Michigan
Kansas City Physician Partners ( Site 1032)
Kansas City, Missouri
Physician Research Collaboration, LLC ( Site 1002)
Lincoln, Nebraska
altoona center for clinical research ( Site 1005)
Duncansville, Pennsylvania
Rheumatology Specialty Center ( Site 1030)
Willow Grove, Pennsylvania
AARA Clinical Research - Murfreesboro Medical Clinic ( Site 1034)
Murfreesboro, Tennessee
Rheumatology Associates ( Site 1026)
Arlington, Texas
Epic Medical Research ( Site 1004)
Red Oak, Texas
Advanced Rheumatology of Houston - Woodlands ( Site 1000)
The Woodlands, Texas
CIUSSS de l'Estrie - CHUS, Hotel-Dieu de Sherbrooke ( Site 1106)
Sherbrooke, Quebec, Canada
Centre de Recherche Musculo-Squelettique ( Site 1101)
Trois-Rivières, Quebec, Canada
Centro de Estudios GyC ( Site 1206)
Santiago, Region M. de Santiago, Chile
Clinica Dermacross ( Site 1203)
Santiago, Region M. de Santiago, Chile
CECIM ( Site 1208)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile-CICUC ( Site 1209)
Santiago, Region M. de Santiago, Chile
Peking University First Hospital ( Site 2511)
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Xiamen University. ( Site 2510)
Xiamen, Fujian, China
The Third Affiliated Hospital, Sun Yat-sen University ( Site 2514)
Guangzhou, Guangdong, China
Xinxiang Central Hospital ( Site 2501)
Xinxiang, Henan, China
Pingxiang People's Hospital ( Site 2512)
Pingxiang, Jiangxi, China
Linfen Central Hospital ( Site 2507)
Linfen, Shanxi, China
PEOPLE'S HOSPITAL OF XINJIANG UYGUR AUTONOMOUS REGION ( Site 2515)
Ürümqi, Xinjiang, China
Taizhou Hospital of Zhejiang Province ( Site 2506)
Linhai, Zhejiang, China
Clinica de la Costa S.A.S. ( Site 1301)
Barranquilla, Atlántico, Colombia
CIREEM SAS ( Site 1304)
Bogota, Cundinamarca, Colombia
Fundación Valle del Lili ( Site 1305)
Cali, Valle del Cauca Department, Colombia
Rheumatologische Schwerpunktpraxis ( Site 1603)
Berlin, Germany
HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg G ( Site 1602)
Hamburg, Germany
Medicover München Ost MVZ ( Site 1607)
München, Bavaria, Germany
Rheuma-Research Lausitz ( Site 1604)
Cottbus, Brandenburg, Germany
Rheumazentrum Ratingen Studienambulanz ( Site 1601)
Ratingen, North Rhine-Westphalia, Germany
Kai Clinic ( Site 2600)
Miyazaki, Japan
Toshin Yoshida Internal Medicine Rheumatology ( Site 2606)
Hanishina-gun, Nagano, Japan
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.